Prime Stocks update: Moving this biotech stock from BUY to a HOLD

When we gave the call of this R&D focused company engaged in the manufacture of enzymes and probiotics, the company had Covid-related challenges but showed promise of growth. It was later also pulled down by consolidation of acquisitions and costs related to new product launches. We therefore knew that the call would take longer to pay off.  The stock went through a significant correction after our initial recommendation as earnings disappointed.

This article is available for Prime Growth subscribers and trial users only

To read the full article

More like this

Become a PrimeInvestor!

Get access to fresh stocks and mutual funds recommendations.

Login to your account